PureTech Health (LON:PRTC) Stock Price Crosses Above 50 Day Moving Average – What’s Next?

PureTech Health plc (LON:PRTC) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 120.91 and traded as high as GBX 122.40. PureTech Health shares last traded at GBX 119.40, with a volume of 2,906,692 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt reaffirmed a “buy” rating and set a GBX 508 price objective on shares of PureTech Health in a research note on Monday, July 13th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, PureTech Health has an average rating of “Buy” and a consensus price target of GBX 508.

PureTech Health Trading Down 1.0%

The company has a quick ratio of 2.51, a current ratio of 6.59 and a debt-to-equity ratio of 6.33. The company’s 50-day moving average is GBX 120.91 and its 200-day moving average is GBX 124.25. The stock has a market capitalization of £292.74 million, a price-to-earnings ratio of -2.60 and a beta of 0.77.

Insider Buying and Selling

In related news, insider Kiran Mazumdar Shaw acquired 93,944 shares of PureTech Health stock in a transaction that occurred on Wednesday, July 29th. The shares were purchased at an average cost of GBX 1 per share, for a total transaction of £939.44. Also, insider Robert Langer purchased 93,944 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were bought at an average price of GBX 1 per share, with a total value of £939.44. Insiders bought a total of 617,569 shares of company stock valued at $18,063,751 in the last ninety days. Company insiders own 13.41% of the company’s stock.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.